DURAFIBER Ag Post-Market Clinical Follow-Up

Inclusion Criteria: Inclusion Criteria to be confirmed at the initial assessment * The subject or must provide written informed consent. * Subjects must be at least eighteen (18) years of age. * Willing and able to make all required study visits. * Able to follow instructions. * Subjects must have a VLU, an ankle brachial pressure index (ABPI) taken within the last 28 days of 0.8-1.3, and must be treated with compression therapy. * The subject must have a wound with an area ≥ 2cm². * The subject's wound must have moderate or high exudate levels. * The subject's reference wound must, in the opinion of the Healthcare Professional, show signs of infection warranting treatment with DURAFIBER Ag. * In the clinician's opinion the subject's wound has an initial bacterial count of \> 104 cfu/g (which will be confirmed following the initial wound biopsy). Inclusion criteria to be confirmed when the biopsy result is recorded: -The subject's wound has a confirmed initial bacterial count of \> 104 cfu/g Exclusion Criteria: * Contraindications or hypersensitivity to the use of the DURAFIBER Ag, ancillary products or their components (e.g. known sensitivity to silver). * Participation in the treatment period of another clinical trial within thirty (30) days of the date of consent. * Subjects with skin features (e.g. tattoos, skin colour, pre-existing scarring) which, in the opinion of the Investigator, will interfere with the study assessments. * Subjects receiving topical antimicrobials or oil-based products (such as petrolatum) at the reference wound surface. * Subjects being treated with immunosuppressive drugs or corticosteroids. * Subjects who have participated previously in this clinical trial and who have healed or been withdrawn. * Subjects with a known history of poor compliance with medical treatment. * Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.